Biodexa Pharmaceuticals Plc

BDRX • Biotechnology

$0.85

▲ +0.05 (+6.21%)

Precio actual

ResultadosÚltimo reporte: 31 dic 2025

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$38,298.224

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.01Liquidez saludable · 2.03Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 31 dic 2025, 12:00 a.m. UTCÚltima actualización de earnings: 27 mar 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.85

Change6.21%

Shares Out45.16K

Market Cap$38.30K

52W Range2.45 - 66.50

Beta1.22

P/E-0.02

P/S0.00

P/B0.01

P/FCF-0.02

EV/Sales0.00

EV/EBITDA0.99

Price$0.85

Change6.21%

Shares Out45.16K

Market Cap$38.30K

52W Range2.45 - 66.50

Beta1.22

P/E-0.02

P/S0.00

P/B0.01

P/FCF-0.02

EV/Sales0.00

EV/EBITDA0.99

EV/FCF1.48

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.01

Current Ratio2.03

Quick Ratio2.03

Volume30.28K

Avg Volume819.24K

EPS Surprise0.01

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

95/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.01Liquidez saludable · 2.03Tendencia de crecimiento negativaRentabilidad débil

Analyst view

No analyst data available now.

Resumen de la compañía

IPO: 12/7/2015

Industria: Biotechnology

P/B i: 0.01

Deuda / Patrimonio i: 0.01

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 2.03

Ratio rápido: 2.03

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Parker Stephen Barry

Transacción: 03/18/2026

OTRO

Cambio

+576

Precio

$475.00

Presentación

03/20/2026

Tipo

OTRO

Turton Simon

Transacción: 03/18/2026

OTRO

Cambio

+288

Precio

$475.00

Presentación

03/18/2026

Tipo

OTRO

Turton Simon

Transacción: 03/18/2026

OTRO

Cambio

Precio

Not reported

Presentación

03/18/2026

Tipo

OTRO

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Parker Stephen Barry	OTRO	+576	$475.00	03/18/2026	03/20/2026
Turton Simon	OTRO	+288	$475.00	03/18/2026	03/18/2026
Turton Simon	OTRO	0	Not reported	03/18/2026	03/18/2026
Powell Fiona Mary	OTRO	+8,750	$7.41	03/18/2026	03/18/2026
de Vries Simon	OTRO	+288	$475.00	03/18/2026	03/18/2026
Stamp Stephen Anthony	OTRO	+15,000	$5.40	03/18/2026	03/18/2026
Merchant Ann Louise	OTRO	+288	$475.00	03/18/2026	03/18/2026

Sobre la compañía

Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.

Fuente - Link

Competidores

BIVI CANF CNSP ESLA GLMD GNPX GRI INM JAGX KZIA

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP

August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has exceeded the half-way point in the recruitment of subjects in its registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis (FAP), NCT06950385. As of today, 87 of a planned 168 subjects have been recruited into the Serenta trial.

GlobeNewsWire

Result of General Meeting

July 29, 2026 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces that at its General Meeting held earlier today, all four resolutions put to the Company's shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at the General Meeting can be found in the Notice of the General Meeting on the Company's website at: https://biodexapharma.com/investors/corporate-governance/#agms.

GlobeNewsWire

Result of General Meeting

July 29, 2026 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) ("Biodexa" or "the Company"), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces that at its General Meeting held earlier today, all four resolutions put to the Company's shareholders were duly passed.

Globe News Wire

Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France

July 28, 2026 Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has held its first round table meeting in Paris, France as part of expanding its support for Familial Adenomatous Polyposis (FAP) patients and prescribers. The sharing of experience and expertise amongst patients, patient advocacy groups and clinicians is informing Biodexa's goal of improving outcomes and quality of life for FAP patients.

GlobeNewsWire

Result of Annual General Meeting

June 30, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of Annual General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers announces that its re-scheduled Annual General Meeting held at 11.00 BST today, ordinary resolutions 1 through 7 passed with majorities of 94%, 73%, 92%, 81%, 81%, 91% and 94%, respectively. Ordinary resolution 8 and special resolution 10 failed to pass.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-03-27	-0.00662	-0.00057	0.00605
2025-09-12	-0.00397	-0.00027	0.0037
2025-04-11	-0.00629	-0.00662	-0.00033
2024-09-26	-0.22354	-0.33495	-0.11141
2024-04-19	-3.54197	-3.54465	-0.00268